Beautiful post by Risk on iflub... I was just aski
Post# of 30029
Posted On: 07/27/2014 5:16:58 PM
Beautiful post by Risk on iflub... I was just asking myself the same questions.
Although, again I think the numbers are conservative. I really see us at a much higher PPS by end of 2014. Funny thing is that this is just pertaining to Lympro. We will also have other catalysts. Nuropro, which wouldn't surprise me if it was talked about as a package deal in with Lympro for the JV already and will ballon the valuation. Wouldn't you want that also if you are backing Lympro and it's all it is?
Then there's the Elazropane for both PD and ADHD, the steady and astonishing updates on manf for Wolfsram, Diabetes etc. Also, will they really split the company and if so when? Before or after up list? Very exciting and lucrative times here people, best of luck to all!
By Riskreturn:
LYMPRO'S NEXT THREE CATALYSTS:
1) THE CONFERENCE ON JULY 31ST where LymPro's newest data will be revealed. If the sens & spec numbers are above 90% we are going to get a boost. Having Beckton Dickenson get those numbers for us really gives us credibility with all the Big Pharmas doing AD clinical trials. Currently, the test they are using to screen their clinical patients is more invasive, more expensive, and less accurate! They will be more than ready to switch over to LymPro.
2) LYMPRO REVENUE GUIDANCE will be given by Gerald a week or so after the 31st Conference. Jason Napodano has said "the revenue opportunity for LymPro under CLIA will be several hundred million." The question is, will that revenue need some ramp up time to get to several hundred million per year, or will we get it in 2015? Watson thinks we'll have 250 million revenue in 2015. I think that is high. The truth is, if we only get 80 million and 50 million of that is our share of the profits, that is a home run! If you multiply 50 million by 8 you get 400 million market cap for LymPro alone. With 800 million outstanding shares that translates to .50 cents per share for LymPro alone!! Revenue Guidance could really boost our pps.
3) LYMPRO PARTNERSHIP ANNOUNCEMENT AT THE END OF SUMMER will also boost our pps. If we get 35 to 50 million up front from a Johnson & Johnson, I could see us trading well above .40 or .50 cents by mid September!!
Although, again I think the numbers are conservative. I really see us at a much higher PPS by end of 2014. Funny thing is that this is just pertaining to Lympro. We will also have other catalysts. Nuropro, which wouldn't surprise me if it was talked about as a package deal in with Lympro for the JV already and will ballon the valuation. Wouldn't you want that also if you are backing Lympro and it's all it is?
Then there's the Elazropane for both PD and ADHD, the steady and astonishing updates on manf for Wolfsram, Diabetes etc. Also, will they really split the company and if so when? Before or after up list? Very exciting and lucrative times here people, best of luck to all!
By Riskreturn:
LYMPRO'S NEXT THREE CATALYSTS:
1) THE CONFERENCE ON JULY 31ST where LymPro's newest data will be revealed. If the sens & spec numbers are above 90% we are going to get a boost. Having Beckton Dickenson get those numbers for us really gives us credibility with all the Big Pharmas doing AD clinical trials. Currently, the test they are using to screen their clinical patients is more invasive, more expensive, and less accurate! They will be more than ready to switch over to LymPro.
2) LYMPRO REVENUE GUIDANCE will be given by Gerald a week or so after the 31st Conference. Jason Napodano has said "the revenue opportunity for LymPro under CLIA will be several hundred million." The question is, will that revenue need some ramp up time to get to several hundred million per year, or will we get it in 2015? Watson thinks we'll have 250 million revenue in 2015. I think that is high. The truth is, if we only get 80 million and 50 million of that is our share of the profits, that is a home run! If you multiply 50 million by 8 you get 400 million market cap for LymPro alone. With 800 million outstanding shares that translates to .50 cents per share for LymPro alone!! Revenue Guidance could really boost our pps.
3) LYMPRO PARTNERSHIP ANNOUNCEMENT AT THE END OF SUMMER will also boost our pps. If we get 35 to 50 million up front from a Johnson & Johnson, I could see us trading well above .40 or .50 cents by mid September!!
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼